Immune cell infusion aims to free ARDS patients from ventilators

NCT ID NCT07706855

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests an experimental therapy called GKL-006RTU, made from a type of immune cell (iNKT cells), for people with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. The trial has two parts: first, a small group receives the cell infusion to check safety; then, a larger group is randomly assigned to receive either the cell therapy or a placebo, both added to standard care. The main goal is to see if the treatment helps patients spend fewer days on a ventilator.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental iNKT cell therapy called GKL-006RTU
What this could lead to
If successful, this could lead to a new treatment that helps people with severe ARDS recover faster and spend less time on a ventilator.
What could go wrong
This is an early-phase trial with only 52 participants, so results may not apply broadly. Cell therapies can cause serious side effects like immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS (ACUTE RESPIRATORY DISTRESS SYNDROME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.